ライフサイエンスコーパス: alpha-blocker

1 addition of an antimuscarinic therapy to an alpha-blocker.

2 verine, and solifenacin), with or without an alpha-blocker.

3 of disease progression during treatment with alpha-blocker.

4 riamterene and hydrochlorothiazide, and 1 an alpha-blocker.

5 lls could be a marker for treatment with TNF-alpha blockers.

6 ing these cell types unlikely targets of TNF-alpha blockers.

7 are normalized in patients treated with TNF-alpha blockers.

8 enzyme inhibitors, and 1 of 1 RCT (100%) of alpha-blockers.

9 Combination therapy of alpha-blocker and 5alpha-reductase inhibitor results in

10 patients benefit from combination therapy of alpha-blocker and 5alpha-reductase inhibitor.

11 omatic benign prostatic hyperplasia is still alpha-blockers and 5alpha-reductase inhibitors.

12 population, such that an interaction between alpha-blockers and prostate cancer risk is clinically re

13 inhibitors, calcium channel blockers (CCBs), alpha-blockers, and angiotensin receptor blockers-was si

14 Medical expulsive therapy with alpha-blockers appears to be efficacious, shortening the

15 alpha-Blockers are no longer recommended as add-on thera

16 ent (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agen

17 e inhibitors, angiotensin-receptor blockers, alpha-blockers, beta-blockers, calcium channel blockers,

18 ical centers were analyzed, including use of alpha-blockers (both selective and nonselective), IFIS,

19 HF-HP and HF-LP received alpha-blockers (chlorpromazine and/or prazosin).

20 t declines in the use of doxazosin and other alpha-blockers coincided with the early termination of t

21 PURPOSE OF REVIEW: To determine whether alpha-blockers, commonly used for the treatment of benig

22 , Enbrel), which is a tumour necrosis factor alpha blocker currently used to treat rheumatoid arthrit

23 zyme inhibitor (lisinopril; n = 8233), or an alpha-blocker (doxazosin; n = 8195).

24 between 1996 and 2002, including changes in alpha-blocker drug prices, generic conversion, drug prom

25 cted comparing the safety and efficacy of an alpha blocker-finasteride combination versus placebo in

26 ior prostate surgery and men who were taking alpha-blockers for urinary tract symptoms, 708 participa

27 Patients given calcium-channel blockers or alpha blockers had a 65% (absolute risk reduction=0.31 9

28 Additionally, tumor necrosis factor-alpha blockers have been shown to be effective in the tr

29 RECENT FINDINGS: Alpha-blockers have been associated with a reduced risk

30 r, this relationship is complex as different alpha-blockers have divergent effects in laboratory stud

31 tors (ACEIs), calcium antagonists (CCBs) and alpha-blockers in preventing one or more major clinical

32 e of antimuscarinics, in combination with an alpha-blocker, in men with an overactive bladder and sum

33 Compared with alpha-blockers, low-dose diuretics were associated with

34 cantly to this decline although cessation of alpha-blocker marketing may have hastened the decline.

35 n patients who were not premedicated with an alpha-blocker (n = 5) had a higher level of systolic blo

36 There were steady increases in alpha-blocker new prescriptions, dispensed prescriptions

37 with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors.

38 Patients premedicated with the alpha-blocker phenoxybenzamine appear to have a reduced

39 2% of patients with IFIS (428/569) had taken alpha-blockers preoperatively (P < .00001).

40 A total of 1254 patients (25.5%) took alpha-blockers preoperatively (selective, 587; nonselect

41 Between 1999 and 2002, new annual alpha-blocker prescription orders declined by 26% (from

42 Treatment options include new alpha-blockers, psychological intervention, and prostate

43 ed during healing, administration of the TNF-alpha blocker reduced apoptosis of bone-lining cells by

44 increase in risk associated with exposure to alpha-blockers require replication and warrant further i

45 whether treatment with tumor necrosis factor alpha blockers results in further increased incidence of

46 ta are provided, doxazosin, and probably all alpha-blockers, should no longer be used as first-line a

47 ies have shown the efficacy of new selective alpha-blockers (silodosin and naftopidil); however, ther

48 veractive bladder) following therapy with an alpha-blocker, the addition of an antimuscarinic therapy

49 ungal therapy and the safety of resuming TNF-alpha blocker therapy after successful treatment of hist

50 Resumption of TNF-alpha blocker therapy also appears safe, assuming that t

51 TNF-alpha blocker therapy was initially discontinued in 95 o

52 atients with recurrence, 2 had restarted TNF-alpha blocker therapy, 1 of whom died.

53 s may complicate tumor necrosis factor (TNF)-alpha blocker therapy.

54 nercept and infliximab have showed these TNF-alpha blockers to be well tolerated and effective in the

55 The routine use of antibiotics and alpha-blockers to treat chronic abacterial prostatitis i

56 Tumor necrosis factor alpha blocker use was associated with better antibody re

57 Tumor necrosis factor alpha blocker use was associated with better serologic r

58 t, there was a slightly higher prevalence of alpha-blocker use in case vs control patients (32% vs 30

59 The pooled risk ratio for alpha blockers was 1.54 (1.29-1.85) and for calcium-chan

60 trials in which calcium-channel blockers or alpha blockers were used to treat ureteral stones were e

61 trials in which calcium-channel blockers or alpha blockers were used to treat urinary stone disease.